DVA — DaVita Inc.

DaVita (DVA) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Operating Income: $482 million, exceeding forecasts by approximately $50 million.
• Adjusted Earnings Per Share (EPS): $2.87.
• Free Cash Flow: $140 million.
• Treatment Volume: Slightly ahead of forecast; treatment per normalized day increased by 40 basis points year-over-year.
• Revenue Per Treatment (RPT): Declined by approximately $5 sequentially but grew about 4% year-over-year.
• Patient Care Cost per Treatment: Flat compared to Q4 2025, lower than expected due to improved productivity.
• General & Administrative (G&A) Costs: Increased by 13% year-over-year due to technology investments.

2. Strategic Updates and Business Highlights

• Integrated Kidney Care (IKC): Achieved significant improvements in CMS' CKCC program, leading to the highest total aggregate savings among participants.
• Technology Investments: Focus on modernizing IT systems and deploying AI solutions to enhance operational efficiency and clinical outcomes. Notable tool introduced: ScheduleHub, for optimizing patient and staffing schedules.
• ACA Plan Enrollment: Trending slightly better than previous expectations, but still facing headwinds from patients opting for lower-level plans.

3. Forward Guidance and Outlook

• Adjusted Operating Income Guidance: Raised to a range of $2.15 billion to $2.25 billion.
• Adjusted EPS Guidance: Increased to $14.10 to $15.20 per share.
• Volume Growth Expectations: Revised from flat to an increase of 25 to 50 basis points for the full year, driven by better underlying performance and patient transfers from Fresenius.
• Debt Expense: Expected to remain flat for the year due to higher share repurchases and interest rates.

4. Bad News, Challenges, or Points of Concern

• Mortality and Admissions: While mortality improved, the underlying trends remain uncertain. Admissions were lower than forecasted, and the impact of clinic closures by Fresenius could affect future volumes.
• Revenue Per Treatment (RPT) Pressure: Despite a strong Q1, RPT growth for the year is expected to be only 1% to 2%, influenced by a decline in commercial mix and higher out-of-pocket costs for patients.
• G&A Costs: Rising faster than revenue, raising concerns about long-term cost management.

5. Notable Q&A Insights

• Volume Commentary: Weather and flu season impacts were in line with expectations, with mortality improvements attributed to underlying trends rather than seasonal factors.
• Market Share Strategy: DaVita is actively positioning itself to capture patients from closed Fresenius centers, though competition remains intense.
• Technology Investments: Executives emphasized the long-term benefits of technology investments, although immediate impacts on operating performance are still unclear.
• Regulatory Environment: Management expressed confidence in compliance due to the nature of dialysis treatment but acknowledged the broader scrutiny on healthcare providers.

This summary encapsulates the key points from DaVita's Q1 2026 earnings call, highlighting both the company's strong performance and the challenges it faces moving forward.